Cargando…

Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo

BACKGROUND: Vitiligo is a chronic autoimmune disease in which the destruction of melanocytes causes white spots on the affected skin. Janus kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK–signal transducer and activator of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdou, Asmaa Gaber, Maraee, Alaa, Yassien, Hossam, Sarhan, Mona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pathologists and the Korean Society for Cytopathology 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250933/ https://www.ncbi.nlm.nih.gov/pubmed/30347972 http://dx.doi.org/10.4132/jptm.2018.09.18

Ejemplares similares

Maspin Expression in Epithelial Skin Tumours: An Immunohistochemical Study
por: Abdou, Asmaa Gaber, et al.
Publicado: (2011)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Tumour-infiltrating Langerhans cells in non-melanoma skin cancer, a clinical and immunohistochemical study
por: Maraee, Alaa, et al.
Publicado: (2020)

Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
por: Samaka, Rehab M, et al.
Publicado: (2019)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo
por: Narla, Shanthi, et al.
Publicado: (2020)

Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
por: Berbert Ferreira, Sineida, et al.
Publicado: (2021)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F
por: Gäbler, Karoline, et al.
Publicado: (2013)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review
por: Wen, Ji, et al.
Publicado: (2021)

Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma
por: Abdou, Asmaa Gaber, et al.
Publicado: (2017)

Versican G1 domain enhances adenoviral-mediated transgene expression and can be modulated by inhibitors of the Janus kinase (JAK)/STAT and Src family kinase pathways
por: Akinfenwa, Patricia Y., et al.
Publicado: (2017)

Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris
por: Farag, Azza Gaber Antar, et al.
Publicado: (2019)

Jak inhibitors in vitiligo: a meta analysis
por: Huang, Xinlyu, et al.
Publicado: (2023)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
por: Morelli, Martina, et al.
Publicado: (2018)

Ab Initio Modeling and Experimental Assessment of Janus Kinase 2 (JAK2) Kinase-Pseudokinase Complex Structure
por: Wan, Xiaobo, et al.
Publicado: (2013)

Essential functions of the Janus kinase 2 (Jak2) during mammary gland development and tumorigenesis
por: Sakamoto, K, et al.
Publicado: (2005)

Pseudocirrhosis in Chronic Budd Chiari Syndrome With Janus Tyrosine Kinase 2 (JAK2) Mutation
por: Lakshmanan, Seetha, et al.
Publicado: (2020)

Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo
por: Gianfaldoni, Serena, et al.
Publicado: (2018)

Differential regulation of Janus kinase 3 (JAK3) in bovine preovulatory follicles and identification of JAK3 interacting proteins in granulosa cells
por: Ndiaye, Kalidou, et al.
Publicado: (2016)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells
Publicado: (1995)

Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors
por: Troncone, Edoardo, et al.
Publicado: (2020)

COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
por: Khaledi, Mansoor, et al.
Publicado: (2022)

Silence of TANK-binding kinase 1 (TBK1) regulates extracellular matrix degradation of chondrocyte in osteoarthritis by janus kinase (JAK)-signal transducer of activators of transcription (STAT) signaling
por: Sun, Peng, et al.
Publicado: (2022)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo
por: Chang, Yuqian, et al.
Publicado: (2023)

Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
por: Kotyla, Przemysław J., et al.
Publicado: (2021)

Association between Polymorphism in the Janus Kinase 2 (JAK2) Gene and Selected Performance Traits in Cattle and Sheep
por: Oster, Nicola, et al.
Publicado: (2023)

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
por: Langley, Paul C
Publicado: (2020)

Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis
por: Schäfer, Arne, et al.
Publicado: (2022)

Fatty acid-binding protein 4 circulating levels in non-segmental vitiligo()
por: Farag, Azza Gaber Antar, et al.
Publicado: (2022)

JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations
por: Menshawey, Rahma, et al.
Publicado: (2020)

Baicalin Ameliorates Collagen-Induced Arthritis Through the Suppression of Janus Kinase 1 (JAK1)/Signal Transducer and Activator of Transcription 3 (STAT3) Signaling in Mice
por: Wang, Chunxiao, et al.
Publicado: (2018)

Macrophage migration inhibitory factor as an incriminating agent in vitiligo
por: Farag, Azza Gaber Antar, et al.
Publicado: (2018)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1
por: Liau, Nicholas P. D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_emhsajbjaaos9c7fjmrhtb2nju